Format

Send to

Choose Destination
Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

Collaborators (320)

Vergote I, Scambia G, Park SY, Song YS, Makarova Y, Trinidad J, Ngan HYS, Bamias A, Aravantinos G, Nam JH, Gorbunova V, Krikunova L, Bae DS, Arija JAA, Mirza MR, Zamagni C, Papandreou C, Raspagliesi F, Lisyanskaya A, Benzaquen AO, Tognon G, Ortega E, Herraez AC, Buscema J, Green A, Burger R, Sakaeva D, Sanchez AR, Ghamande S, King L, Petru E, Peen U, Takeuchi S, Ushijima K, Martin AG, Kamelle S, Carney M, Marth C, Forget F, Bentley J, Sehouli J, Colombo N, Zola P, Kato H, Fadeeva N, Gotovkin E, Vladimirov V, Marin MR, Alia EG, Shahin M, Bhoola S, Tewari K, Anderson D, Honhon B, Pelgrims JG, Oza A, Jimenez JG, Hansen V, O'Malley D, Benjamin I, Renard V, Van den Bulck H, Meier W, Haenle C, Koumakis G, Yokota H, Popov V, Bradley W, Wenham R, Reid R, McNamara D, Friedman R, Barlin J, Spirtos N, Chapman J, Sevelda P, Huizing M, Lamot C, Goffin F, Hondt LD, Covens A, Spadafora S, Rautenberg B, Reimer T, Möbus V, Hilpert F, Gropp-Meier M, Savarese A, Pignata S, Verderame F, Mizuno M, Takano H, Ottevanger P, Velasco AP, Palacio-Vazquez I, Law A, McIntyre K, Teneriello M, Fields A, Lentz S, Street D, Schwartz B, Mannel R, Lim P, Pulaski H, Janni W, Zorr A, Karck U, Cheng ACK, Sorio R, Gridelli C, Aoki D, Oishi T, Hirashima Y, Boere I, Ferrer EF, Braly P, Wilks S, Lee C, Schilder J, Veljovich D, Secord A, Davis K, Rojas-Espaillat L, Lele S, DePasquale S, Squatrito R, Schauer C, Dirix L, Vuylsteke P, Joosens E, Provencher D, Lueck HJ, Hein A, Burges A, Canzler U, Park-Simon TW, Griesinger F, Gadducci A, Alabiso O, Okamoto A, Sawasaki T, Saito T, Ibañez AH, Calomeni C, Spillman M, Choksi J, Taylor N, Muller C, Moore D, DiSilvestro P, Cunningham M, Rose P, Oppelt P, Verhoeven D, Graas MP, Ghatage P, Tonkin K, Kurzeder C, Schnappauf B, Müller V, Schmalzrie H, Kalofonos H, Bruzzone M, Kroep J, Diaz CC, Garcia JM, Polo SH, Garrison M, Rocconi R, Andrews S, Bristow R, McHale M, Basil J, Rose P, Houck Iii W, Bell M, Cosin J, Modesitt S, Kendrick J, Wade Iii J, Wong C, Evans A, Buekers T, Vanderkwaak T, Ferriss J, Darus C, DAndre S, Higgins R, Monk B, Bakkum-Gamez J, DeMars L, Van Le L, Rose P, Puls L, Trehan S, LaPolla J, Michelson ED, Merchant J, Peterson C, Reid G, Seago D, Zweizig S, Gajewski W, Panwalkar A, Leikermoser R, Bogner G, Debruyne P, D'hondt R, Berteloot P, Kerger J, Biagi J, Castonguay V, Welch S, Muhic A, Heubner M, Grischke EM, Rack B, Fleisch M, Lordick F, Pectasides D, Papandreou C, Ho WM, Selvaggi L, Vasquez FM, Villanueva WOB, Alavez AM, Kessels L, Bertran AS, Fernandez CM, Fabregat MB, Del Prete S, Elkas J, Cecchi G, Kumar P, Huh W, Messing M, Karimi M, Kelley A, Edraki B, Mutch D, Leiserowitz G, Anderson J, Lentz S, Chambers S, Morris R, Waggoner S, Gordon A, Method M, Johnson P, Lord R, Drake J, Sivarajan K, Midathada M, Rice K, Wadsworth T, Pavelka J, Edwards R, Miller DS, Ford PL, Hurteau J, Bender D, Schimp V, Creasman W, Lerner R, Chamberlain D, Kueck A, McDonald J, Malad S, Robinson-Bennett B, Davidson S, Krivak T, Lestingi T, Arango H, Berard P, Finkelstein K, Gaur R, Krasner C, Ueland F, Talmage L, Yamada S, Sutton G, Potkul R, Drake J, Prasad-Hayes M, Osborne J, Celano P, Thigpen J, Sharma S, Schilder R, Tammela J, Kemeny M, Brown A, Eisenhauer E, Williams J, Rowland K, Nahum K, Burke J, Dar Z, Fleming N, Gibb R, Guirguis A, Herzog T, John V, Kumar S, Kamat A, Kassar M, Krasner C, Leitao M, Levine L, Mendez L, Patel D, Berry E, Warshal D, Wolf J, Zarwan C, Collins Y, Spitzer G, Miller B, Einstein M.

Author information

1
Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium; European Network of Gynaecological Oncological Trial groups (ENGOT), Divison of Gynecologic Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium. Electronic address: ignace.vergote@uzleuven.be.
2
Multicenter Italian Trials in Ovarian Cancer Society (MITO), Rome, Italy; Fondazione Policlinico Universitario A Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica, Rome, Italy.
3
Gynecologic Oncology Group, James Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
4
Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium; Department of Development and Regeneration, KU Leuven, Leuven, Belgium; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, Netherlands.
5
National Cancer Center, Goyang, South Korea.
6
Grupo Español de Investigación en Cáncer de Ovario (GEICO), Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
7
Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO), Department of Gynecology and Obstetrics, AGO-Germany and Evangelic Hospital Düsseldorf, Düsseldorf, Germany.
8
Department of Clinical Therapeutics, Alexandra Hospital, National & Kapodistrian University of Athens, Athens, Greece; Hellenic Cooperative Oncology Group (HECOG), Athens, Greece.
9
Mario Negri Gynecologic Oncology Group (MANGO), European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy; Università Milano Bicocca, Milan, Italy.
10
Gynecologic Oncology Group, Department of Gynecologic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
11
Division of Gynecologic Oncology, Toronto Sunnybrook Regional Cancer Center, University of Toronto, Toronto, ON, Canada.
12
Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO)-Austria, Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.
13
Nordic Society of Gynaecological Oncology (NSGO), Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
14
Dutch Gynecological Oncology Group (DCOG), Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
15
Global Development Oncology, Amgen, Thousand Oaks, CA, USA.
16
Gynecologic Oncology Group, Arizona Oncology (US Oncology Network), University of Arizona, Phoenix, AZ, USA; Creighton University, Phoenix, AZ, USA.

Abstract

BACKGROUND:

Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2, improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial.

METHODS:

TRINOVA-3, a multicentre, multinational, phase 3, double-blind study, was done at 206 investigational sites (hospitals and cancer centres) in 14 countries. Eligible patients were aged 18 years or older with biopsy-confirmed International Federation of Gynecology and Obstetrics (FIGO) stage III to IV epithelial ovarian, primary peritoneal, or fallopian tube cancers, and an ECOG performance status of 0 or 1. Eligible patients were randomly assigned (2:1) using a permuted block method (block size of six patients) to receive six cycles of paclitaxel (175 mg/m2) and carboplatin (area under the serum concentration-time curve 5 or 6) every 3 weeks, plus weekly intravenous trebananib 15 mg/kg or placebo. Maintenance therapy with trebananib or placebo continued for up to 18 additional months. The primary endpoint was progression-free survival, as assessed by the investigators, in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01493505, and is complete.

FINDINGS:

Between Jan 30, 2012, and Feb 25, 2014, 1164 patients were screened and 1015 eligible patients were randomly allocated to treatment (678 to trebananib and 337 to placebo). After a median follow-up of 27·4 months (IQR 17·7-34·2), 626 patients had progression-free survival events (405 [60%] of 678 in the trebananib group and 221 [66%] of 337 in the placebo group). Median progression-free survival did not differ between the trebananib group (15·9 months [15·0-17·6]) and the placebo group (15·0 months [12·6-16·1]) groups (hazard ratio 0·93 [95% CI 0·79-1·09]; p=0·36). 512 (76%) of 675 patients in the trebananib group and 237 (71%) of 336 in the placebo group had grade 3 or worse treatment-emergent adverse events; of which the most common events were neutropenia (trebananib 238 [35%] vs placebo 126 [38%]) anaemia (76 [11%] vs 40 [12%]), and leucopenia (81 [12%] vs 35 [10%]). 269 (40%) patients in the trebananib group and 104 (31%) in the placebo group had serious adverse events. Two fatal adverse events in the trebananib group were considered related to trebananib, paclitaxel, and carboplatin (lung infection and neutropenic colitis); two were considered to be related to paclitaxel and carboplatin (general physical health deterioration and platelet count decreased). No treatment-related fatal adverse events occurred in the placebo group.

INTERPRETATION:

Trebananib plus carboplatin and paclitaxel did not improve progression-free survival as first-line treatment for advanced ovarian cancer. The combination of trebananib plus carboplatin and paclitaxel did not produce new safety signals. These results show that trebananib in combination with carboplatin and paclitaxel is minimally effective in this patient population.

FUNDING:

Amgen.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center